July 24, 2023 (Tucson, Ariz.) – Applications for the 2023 IdeaFunding competition are live and startups can submit applications before August 28, 2023. IdeaFunding is Southern Arizona’s largest and longest entrepreneurial conference and pitch competition, where this year over $70,000 in prize funding will be awarded to Arizona companies. IdeaFunding is co-led by Startup Tucson and the University of Arizona Center for Innovation (UACI) and presented by the Arizona Commerce Authority. Continue reading
Category Archives: AZBio News
Nectero Medical Receives FDA Clearance of IND Application to Initiate Phase II/III Clinical Trial of Nectero EAST® System for Treatment of Small- to Mid-Sized Abdominal Aortic Aneurysms
Pivotal trial to be conducted at multiple sites, primarily in the U.S., using novel single-use, endovascular system comprised of a dual-balloon delivery catheter and stabilizer mixture containing pentagalloyl glucoseContinue reading
Erroneous genetic sequences identified for the first time in specific cells of ALS and frontotemporal dementia patients
Gene splicing defect known as “cryptic exons” detected using single-nuclei RNA sequencingContinue reading
The Foundation for Angelman Syndrome Therapeutics to Contribute Data to C-Path’s RDCA-DAP, Accelerating Neurological Disease Research and Therapeutic Development
TUCSON, Ariz., July 19, 2023 — Critical Path Institute (C-Path) announced today that the Foundation for Angelman Syndrome Therapeutics (FAST), a nonprofit organization dedicated to finding a cure for this genetic disorder, have contributed data from the Global Angelman Syndrome Registry to the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), managed by C-Path.Continue reading
Ivy Brain Tumor Center Opens Novel Clinical Trial to Test Direct-to-Tumor Drug Delivery Method
- Innovative technique aims to bypass the most difficult barrier in brain cancer treatment
Aqualung Therapeutics Receives FDA Clearance To Proceed With the P2A PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients
- Aqualung Therapeutics will initiate moderate/severe ARDS patient recruitment for U.S. and Australia hospital sites in August 2023.
- Aqualung appoints Jackson Streeter MD to their board of directors bringing expertise to Aqualung to support advancing of ALT-100 mAb as a novel therapeutic for inflammatory and fibrotic diseases (ARDS, radiation-induced lung fibrosis, pulmonary arterial hypertension)
CAMI receives $4M financial investment from Maricopa County
TUCSON, Arizona — The University of Arizona Health Sciences Center for Advanced Molecular and Immunological Therapies received a strong vote of support from the Maricopa County Board of Supervisors with the June 28 approval of $4 million in funding for the life sciences innovation hub being developed on the Phoenix Bioscience Core in downtown Phoenix.Continue reading
Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year
Castle also earns national recognition through five Top Workplaces Culture Excellence Awards — Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & ValuesContinue reading
PathogenDx’s New Rapid, Single Test Detects Salmonella and 13 Serotypes in Poultry as Foodborne Illness Remains a Significant Threat to Public Health in the US
Serotypes Responsible for the Vast Majority of All Harmful Salmonella Infections Are Rapidly Identified in One Efficient Test – in One Lab ShiftContinue reading
C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships
AMSTERDAM and TUCSON, Ariz., July 18, 2023 — Critical Path Institute (C-Path) announced today the completion of the integration of C-Path Ltd. in Dublin, Ireland, into the C-Path nonprofit in Amsterdam, Netherlands. This integration will enable C-Path to increase its activity in Europe and broaden its global operations. C-Path operates in Europe as a nonprofit organisation that builds consensus among its stakeholders from around the world to improve public health. The organisation shares expertise, data, risks and costs to move regulatory science forward.Continue reading